The third edition of the Dutch ATMP Summit will all be about affordable ATMP production
March 6th 2024, Bussum
The third edition of the Dutch ATMP Summit is entirely focused on ‘Affordable Production of Advanced Therapy Medicinal Products (ATMPs)‘. This event unites leading professionals from the sector to delve deeply into the challenges and solutions for making the production of ATMPs more cost-effective.
Throughout the day, there will be various presentations where speakers will discuss different aspects of this theme.
A key feature of the event is the panel discussion. Here, experts will share strategies and insights crucial for reducing costs and enhancing the accessibility of ATMPs. This discussion is an essential opportunity for participants to engage in dialogue about shaping the future of ATMPs in affordable healthcare.
Additionally, the summit offers excellent networking opportunities, allowing attendees to connect with peers, exchange ideas, and build professional relationships, further enriching the experience and potential collaborations in the field of ATMPs.
We look forward to seeing you at the 3rd Dutch ATMP Summit.
The third edition of the Dutch ATMP Summit is entirely focused on the theme ‘Affordable Production of Advanced Therapy Medicinal Products (ATMPs)‘. This event unites leading professionals from the sector to delve deeply into the challenges and solutions for making the production of ATMPs more cost-effective.
Throughout the day, there will be various presentations where speakers will discuss different aspects of this theme,
A key feature of the event is the panel discussion. Here, experts will share strategies and insights in an interactive environment, crucial for reducing costs and enhancing the accessibility of ATMPs. This discussion is an essential opportunity for participants to engage in significant dialogue about shaping the future of ATMPs in affordable healthcare.
Additionally, the summit offers excellent networking opportunities, allowing attendees to connect with peers, exchange ideas, and build professional relationships, further enriching the experience and potential collaborations in the field of ATMPs.
We look forward to seeing you at the 3rd Dutch ATMP Summit.
Full day program
08:30 – 09:00 registration & walk-in
We will start the program with a cup of coffee and some snacks
09:00 – 09:15 welcome
After a warm welcome from our CCO Edwin van den Bos, the host of the day, Frank van Engelenburg, will kick-off the program.
09:15 – 10:30 presentations
- Daniël Warmerdam (FAST): Future Affordable Sustainable Therapy Development
- Eddy Breed (Progress): How rules affect the design of clean rooms. Solutions from the field.
10:30 – 11:00 coffee break & networking
Enjoy some coffee and refreshments and get ready for the next presentation
11:00 – 11:45 presentation
- prof. dr. Edwin Bremer (UMCG/DARE-NL): Future Affordable Sustainable Therapy Development
11:45 – 13:00 lunch & ice breaker & networking
Enjoy a well prepared lunch and get ready for the next part of the Dutch ATMP Summit
13:00 – 14:30 presentations
- Marten Hansen (Amsterdam Cell Therapy Center): T.B.A.
- Joost van den Berg (Galapagos): Experience and challenges in decentralized manufacturing and clinical application of CAR-Ts
14:30 – 15:00 break & networking
Enjoy some coffee and refreshments and get ready for the final presentation
15:00 – 15:45 presentation
- T.B.A.
15:45 – 16:15 Panel Discussion
Theme: How to Make ATMPs Affordable?
16:15 – 16:30 round-up & closing of the Summit
16:30 – 18:00 Networking drinks
Speakers
Daniël Warmerdam
Senior advisor, FAST (Centre for Future Affordable Sustainable Therapy Development)
Dr. Daniël Warmerdam, a Ph.D. holder in molecular biology with extensive research experience, has been a driving force in establishing multiple CRISPR facilities within academia. He has played a central role in coordinating initiatives for therapy development and diagnostics across diverse subsidiary research programs by ZonMw, including those dedicated to addressing challenges posed by COVID-19 and pandemic preparedness. Currently serving as a Senior Advisor at the Centre for Future Affordable Sustainable Therapy development (FAST), Dr. Warmerdam actively leverages his research and policymaking expertise to drive transformative advancements in innovative therapies. His commitment lies in reshaping the healthcare and therapy development landscape, advocating for faster, smarter, better, and more cost-effective approaches to the development, production, and accessibility of new therapies for patients.
Eddy Breed
Senior Consultant, Progress – Experts in Life Sciences
Eddy has 20 years of experience within the pharma industry in the fields of monoclonal antibodies, vaccines, ATMPs and veterinary medicines. He started his career in Process Development and Tech Transfer at Janssen Pharmaceuticals. 6 years ago he joined Progress Life Sciences, where he worked on projects to design, build, qualify and/or start-up new manufacturing facilities in various roles (Project Manager, GMP readiness lead, Technology Integrator and C&Q coordinator).
prof. dr. Edwin Bremer
UMCG/DARE-NL
Tenure track professor Immunohematology and head of the Cellular Therapy Processing Facility at the Department of Hematology, University Medical Center Groningen. Management team DARE/NL & (co-)coordinator work package 4, DARE/NL.
Marten Hansen
CEO, Amsterdam Cell Therapy Center B.V.
Marten Hansen (PhD), CEO of Amsterdam Cell Therapy Center B.V., has worked for more than 10 years in research & development, production of TIL, cultivation of blood (artificial blood) and CAR-T therapies for clinical trials. In addition, he is the head of the Laboratory for Cell Therapy at Sanquin Blood Supply Foundation.
Joost van den Berg
Head Development, CellPoint (Galapagos)
Joost van den Berg (PharmD, PhD), Head of Process Development at CellPoint (now Galapagos) has worked for more than 15 years in research & development, clinical trials and GMP Production of T-cells & cancer vaccines, all in the field of Immune-Oncology. Before joining CellPoint/Galapagos, he was head of the BioTherapeutics Unit at the Netherlands Cancer Institute (NKI), the Antoni van Leeuwenhoek hospital.
Speakers
Daniël Warmerdam
Senior advisor, FAST (Centre for Future Affordable Sustainable Therapy Development)
Eddy Breed
Senior Consultant, Progress – Experts in Life Sciences
prof. dr. Edwin Bremer
UMCG/DARE-NL
Marten Hansen
Head Laboratory, Amsterdam Cell Therapy Center
Joost van den Berg
Head Development, Galapagos
Regular ticket
access to the Dutch AMTP Summit at March 6th 2024.
315,- excl VAT
Dutch ATMP Summit 2024
With this ticket you will get access the the Dutch ATMP Summit on Wednesday March 6th 2024 in Bussum. You can join all the talks of our speakers and meet your colleagues in the field during networking drinks. During the day there are refreshments.
Second ticket for half of the price.
Presentations
Future Affordable Sustainable Therapy Development (dr. Daniël Warmerdam)
To be announced.
Design considerations for ATMP cleanrooms (Eddy Breed, MSc)
To be announced.
Setup of a Dutch academic GMP vector manufacturing platform: Lessons learnt in CAR-T productions at the UMCG (prof. dr. Edwin Bremer)
How to establish a Dutch academic vector manufacturing platform that will facilitate and guide translation of preclinical research and early phase I/II clinical trials by providing centralized and streamlined EU-GMP compliant manufacturing capabilities. The Dutch platform for cancer-specific ATMP Research (DARE-NL) is a new partnership (with UMCG as partner) which was established to accelerate clinical testing of novel oncological ATMPs to ensure timely and sustainable access to potentially curative treatment options for cancer patients. The Hematology department of the UMCG plays an important role within DARE-NL in setting up a central platform for biological raw materials and technologies for academic centers. This platform focuses, among other things, on the development of viral vectors for the new generation of cell and gene therapies. This will accelerate the production and clinical application of such revolutionary therapies, including CAR-T therapy, in academic centers. At the UMCG, the Hematology department works together with the pharmacy to make CAR T cells for the treatment of lymphoma.
Experience and challenges in decentralized manufacturing and clinical application of CAR-Ts (Joost van den Berg, PhD)
At Galapagos, we designed an decentralized CAR-T manufacturing and supply model, using state-of-art technology.Clinical centers of excellence are selected, having experienced clinical teams and a local cell processing facility. The centers are provided with Lonza’s Cocoon™ platform, a fully closed and automated manufacturing device, a kit comprising CAR-T and QC reagents, and full training and support. Clinicians are thereby enabled to schedule and perform CAR-T treatments with a week vein-to-vein time, with simplified logistics compared to conventional centralized production. Experiences and logistical challenges and improvements will be discussed.
Regular ticket
access to the Dutch AMTP Summit at March 15th 2023.
299,- excl VAT
Dutch ATMP Summit 2023
With this ticket you will get access the the Dutch ATMP Summit on Wednesday March 15th 2023 in Amsterdam. You can join all the talks of our speakers and meet your colleagues in the field during networking drinks. During the day there are refreshments.
Second ticket for half of the price!
This years edition of the Dutch ATMP Summit will take place at Fier in Bussum.
Doctor Abraham Kuyperlaan 1-A
1402 SB Bussum
About us
This summit is an initiative from Progress - Experts in Life Sciences
We work together with our clients, in order to obtain their goals. We work as a team to reach to the top. Progress is an independent consultancy company with customers in the pharmaceutical and biotechnology industries and in the healthcare sector. We provide project management, engineering & C&Q, CMC and Quality services.
About us
This summit is an initiative from Progress - Experts in Life Sciences
We work together with our clients, in order to obtain their goals. We work as a team to reach to the top. Progress is an independent consultancy company with customers in the pharmaceutical and biotechnology industries and in the healthcare sector. We operate internationally, project management, engineering & C&Q, CMC and Quality services.
Contact
Progress – Experts in Life Sciences
Bijlmermeerstraat 20
2131 HG Hoofddorp
+31 (0) 23 563 50 16
